title: Prospective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions.
abstract: BACKGROUND
  Although the safety and effectiveness of Drug-Eluting Stents (DES) has been established extensively, reports on long term clinical outcome with angiographic findings in patients with long coronary artery lesions are not many.
  
  
  METHODS
  In this single-center prospective registry of 100 patients, a total of 110 denovo long lesions (>20 mm) were treated with Resolute Zotarolimus Eluting Stent (R-ZES). The patients were followed up clinically at 3, 6 and 12 months and follow up coronary angiography was performed at 9-months. The primary end point was one year rate of target lesion failure (TLF) which is a composite of cardiac death, target lesion myocardial infarction or ischemia driven target lesion revascularization (TLR). The secondary end points included definite or probable stent thrombosis, 9-month angiographic restenosis and late lumen loss.
  
  
  RESULTS
  The mean age of patients was 58.7 ± 9.50 years with prevalence of diabetes as high as 60%. The mean lesion length was 24.67 ± 4.87 mm with a mean reference vessel diameter of 2.85 ± 0.32 mm and 67.3% were Type C lesions (ACC/AHA classification). Two patients died during follow-up, of which one was non-cardiac death. One patient had target vessel myocardial infarction and five patients (4.5%) had ischemia driven TLR. The incidence of TLF was 6.36%. Binary restenosis was seen in 7 out of 93 lesions (7.5%). Median late lumen loss at 9 month was 0.22 mm. No stent thrombosis was noted in the study.
  
  
  CONCLUSIONS
  Implantation of R-ZES in real-world patients with long coronary artery lesions is safe with comparable efficacy to what is observed in the treatment of less complex lesions.
authors.affiliation: Chairman, Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, Thiruvananthapuram, Kerala, India. Electronic address: bahuleyan2001@yahoo.co.uk.
authors.forename: C G
authors.initials: CG
authors.lastname: Bahuleyan
authors.affiliation: Consultant Cardiologist, Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, Thiruvananthapuram, Kerala, India.
authors.forename: V V
authors.initials: VV
authors.lastname: Krishna Kumar
authors.affiliation: Consultant Cardiologist, Cardiovascular Centre, Ananthapuri Hospitals and Research Institute, Thiruvananthapuram, Kerala, India.
authors.forename: Shifas
authors.initials: S
authors.lastname: Babu
mesh_terms: D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000601:surgery*; D003331:Coronary Vessels / Q000000981:diagnostic imaging* / Q000601:surgery; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D011446:Prospective Studies; D011474:Prosthesis Design; D012307:Risk Factors; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C489443:zotarolimus; D020123:Sirolimus
keywords: Late lumen loss; Long lesion; Stent thrombosis; Target lesion failure; Zotarolimus Eluting Stent